JP2018533947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018533947A5 JP2018533947A5 JP2018521290A JP2018521290A JP2018533947A5 JP 2018533947 A5 JP2018533947 A5 JP 2018533947A5 JP 2018521290 A JP2018521290 A JP 2018521290A JP 2018521290 A JP2018521290 A JP 2018521290A JP 2018533947 A5 JP2018533947 A5 JP 2018533947A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- receptor agonist
- domain
- agonist protein
- cd27l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245689P | 2015-10-23 | 2015-10-23 | |
| US62/245,689 | 2015-10-23 | ||
| PCT/EP2016/075579 WO2017068192A1 (en) | 2015-10-23 | 2016-10-24 | Single-chain cd27-receptor agonist proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018533947A JP2018533947A (ja) | 2018-11-22 |
| JP2018533947A5 true JP2018533947A5 (enExample) | 2019-12-05 |
| JP6917368B2 JP6917368B2 (ja) | 2021-08-11 |
Family
ID=57241060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521290A Active JP6917368B2 (ja) | 2015-10-23 | 2016-10-24 | 一本鎖ｃｄ２７受容体アゴニストタンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10844108B2 (enExample) |
| EP (1) | EP3364995B1 (enExample) |
| JP (1) | JP6917368B2 (enExample) |
| CN (1) | CN108430492B (enExample) |
| AU (1) | AU2016341409B2 (enExample) |
| CA (1) | CA3002602C (enExample) |
| WO (1) | WO2017068192A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017068183A1 (en) * | 2015-10-23 | 2017-04-27 | Apogenix Ag | Single-chain cd137-receptor agonist proteins |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| RU2769513C2 (ru) | 2017-01-05 | 2022-04-01 | Кахр Медикал Лтд. | Слитый белок pd1-4-1bbl и способы его применения |
| PL3565828T3 (pl) | 2017-01-05 | 2022-04-04 | Kahr Medical Ltd. | Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania |
| WO2018127918A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirp alpha-cd70 fusion protein and methods of use thereof |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| CA3104778A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| EP4041410A4 (en) * | 2019-10-08 | 2023-12-06 | Fred Hutchinson Cancer Center | GENETICALLY MODIFIED TRIMERIC CD70 PROTEINS AND THEIR USES |
| CN115836084A (zh) | 2020-05-15 | 2023-03-21 | 阿珀吉尼科斯股份公司 | 多特异性免疫调节剂 |
| WO2023088876A1 (en) | 2021-11-16 | 2023-05-25 | Apogenix Ag | Multi-specific immune modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573924A (en) * | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| ATE462725T1 (de) * | 1998-08-25 | 2010-04-15 | Merck Patent Gmbh | Expression und export von angiostatin und endostatin als immunofusins |
| AR025984A1 (es) | 1999-10-07 | 2002-12-26 | Maxygen Aps | Polipeptidos oligomericos de cadena simple |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CA2314199A1 (en) | 2000-07-21 | 2002-01-21 | Robert Simoneau | C-chip |
| DK1606318T3 (da) | 2003-03-26 | 2009-11-02 | Apogenix Gmbh | Forbedrede Fc-fusionsproteiner |
| DE102004014983A1 (de) | 2004-03-26 | 2005-10-20 | Univ Stuttgart | Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung |
| JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するＦｃ変異体 |
| US20080124340A1 (en) * | 2006-04-14 | 2008-05-29 | Borges Luis G | Erythropoietin receptor agonists |
| EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| EP3103875A1 (en) | 2008-07-21 | 2016-12-14 | Apogenix AG | Tnfsf single chain molecules |
| NZ602892A (en) * | 2010-04-13 | 2014-08-29 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
| AU2012356894B2 (en) * | 2011-12-23 | 2018-01-18 | Araris Biotech Ltd. | Enzymatic conjugation of polypeptides |
| BR122020002414B1 (pt) * | 2012-03-15 | 2022-03-03 | Janssen Biotech, Inc | Uso de anticorpos anti-cd27 humanos |
| RU2016107426A (ru) * | 2013-08-02 | 2017-09-07 | Адуро Байотек Холдингс, Юроуп Б.В. | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета |
| NO2776305T3 (enExample) | 2014-04-23 | 2018-01-27 |
-
2016
- 2016-10-24 EP EP16791344.1A patent/EP3364995B1/en active Active
- 2016-10-24 WO PCT/EP2016/075579 patent/WO2017068192A1/en not_active Ceased
- 2016-10-24 CA CA3002602A patent/CA3002602C/en active Active
- 2016-10-24 AU AU2016341409A patent/AU2016341409B2/en active Active
- 2016-10-24 JP JP2018521290A patent/JP6917368B2/ja active Active
- 2016-10-24 CN CN201680073684.5A patent/CN108430492B/zh active Active
-
2018
- 2018-04-19 US US15/956,964 patent/US10844108B2/en active Active
-
2020
- 2020-11-17 US US16/950,755 patent/US20210061880A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017141727A (ru) | Одноцепочечные белки-агонисты рецептора cd40 | |
| JP2019500850A5 (enExample) | ||
| US7803769B2 (en) | OSK1 peptide analogs and pharmaceutical compositions | |
| JP6272907B2 (ja) | 代謝障害の処置における組成物及び使用方法 | |
| CA2748314C (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP7536294B2 (ja) | 抗体のＦｃ領域改変体 | |
| JP6040464B2 (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
| CN103403019B (zh) | 具有增强的作用持续时间的工程化多肽 | |
| JP2018533948A5 (enExample) | ||
| TW202225183A (zh) | Gdf15融合蛋白及其用途 | |
| NZ562201A (en) | Toxin peptides with extended blood halflife | |
| EP2989240A2 (en) | Interleukin-10 compositions and uses thereof | |
| JP2010501191A5 (enExample) | ||
| US20150037333A1 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| US20090252703A1 (en) | Use of alcohol co-solvents to improve pegylation reaction yields | |
| AU2016242905A1 (en) | Protoxin-II variants and methods of use | |
| JP2019501631A5 (enExample) | ||
| JP2018518485A (ja) | プロテアーゼ耐性脂質付加ｇｌｐ−１類似体 | |
| EP4294826A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| EP2597102A1 (en) | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 | |
| US20240058422A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
| ZA200709701B (en) | Toxin peptide therapeutic agents | |
| NZ741431B2 (en) | Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same | |
| WO2014014816A2 (en) | Methods of treating glucose metabolism disorders | |
| WO2013151627A1 (en) | Methods of treating glucose metabolism disorders |